COMMUNIQUÉS West-GlobeNewswire

Mental Health Awareness Month: TPN.health Solves the Access Crisis Costing Self-Insured Stakeholders, Health Plans and Members the Care They Deserve
12/05/2026
NEW ORLEANS, May 12, 2026 (GLOBE NEWSWIRE) -- TPN.health , the operating system for behavioral health, is redefining what access to mental health care means for self-funded employers, health plans and the millions of [...]
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
12/05/2026
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications TAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
Becker’s Names Leap Distributors CEO Allen Mason to 2026 Great Leaders in Healthcare List
12/05/2026
DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Becker’s Hospital Review has named Leap Distributors Co-founder and CEO Allen Mason to the 2026 list of Great Leaders in Healthcare. Mason is included in the Companies section, [...]
Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research
12/05/2026
Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Fortis Life Sciences [...]
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
12/05/2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
12/05/2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
12/05/2026
ENvue™ Navigation Platform adopted as the standard of care for bedside feeding tube placement across the integrated health network TYLER, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc . (NASDAQ: FEED) (“ [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell [...]
Adagene to Participate in Two Upcoming Investor Conferences
12/05/2026
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform
12/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
12/05/2026
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright [...]
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
12/05/2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden [...]
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 [...]
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, “Medtronic”), the Company’s strategic [...]

Pages